SCYNEXIS Announces Interim Results from Phase 2 Study of Oral SCY-078 in Patients with Invasive Candidiasis Aug 1, 2016
SCYNEXIS Announces Pricing of $22.5 Million Public Offering of Common Stock and Warrants Jun 21, 2016
SCYNEXIS Inc. Presents New Clinical and Non-Clinical Data Confirming the Potential of SCY-078 as a Novel Treatment for Life-threatening Fungal Infections Jun 20, 2016
SCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at ASM Microbe 2016 Jun 10, 2016
SCYNEXIS, Inc. Announces Positive Results in its Proof-of-Concept Phase 2 Study of SCY-078, the First Member of a Novel Class of Glucan Synthase Inhibitors Jun 8, 2016
SCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Candida Infections May 13, 2016
